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A 3D in vitro model reveals differences in the 
astrocyte response elicited by potential stem cell 
therapies for CNS injury
Stem cells have the potential to provide new 
approaches for the treatment of CNS disorders, 
either through replacing lost or malfunction-
ing cells directly or through other mechanisms 
including angiogenesis, remyelination, neuro-
protection and modulation of inflammation [1]. 
Various stem cells have been shown to be benefi-
cial in animal models of human CNS diseases, 
with adult stem cells derived from bone marrow, 
adipose and skin tissues being of particular inter-
est owing to their potential as autologous sources. 
In order for stem cell therapies to be translated 
successfully into the clinic it is essential to under-
stand more about their effects. This is often dif-
ficult to study in animal models owing to the 
complexity of the CNS microenvironment and 
the challenges involved in controlling variables 
and monitoring cell-level responses. 
Cell culture systems provide a more reduction-
ist tool to complement animal models, allowing 
specific cellular responses and interactions to be 
studied in a carefully defined environment, with 
greater reproducibility and more options for con-
tinuous monitoring than can be achieved in vivo. 
Therefore, it is common for researchers to use 
co-culture models during the development of cell 
therapies, for example to study their mechanism 
of action on specific neural cell types [2–6].
However, one important cellular response 
that could play a critical role in the effectiveness 
and safety of cell therapies for CNS repair, and 
has not yet been routinely tested in vitro, is the 
extent to which transplanted cells might potenti-
ate reactive astrogliosis and glial scarring [7]. The 
glial scar forms following CNS injury, presenting 
a physical and chemical impediment to neuronal 
regeneration. It is comprised predominately of 
reactive astrocytes, which exhibit a character-
istic hypertrophic ramified morph ology with 
increased expression of GFAP. The extent and 
persistence of the glial scar is a feature that is 
of great interest to researchers in regenerative 
medicine, since modifying the glial response fol-
lowing CNS damage has been associated with 
changes in functional outcome in animal mod-
els [8,9]. While glial scarring has some beneficial 
effects following CNS damage [10], researchers 
generally seek to minimize the extent of addi-
tional reactive gliosis associated with implanted 
materials and cells. Monitoring the extent of 
GFAP expression around a graft is a common 
output in experiments using animal models. 
However, such models offer only a snapshot 
view post-mortem and have numerous complex 
pathways that could cause changes in reactive 
gliosis, therefore limiting the ability of research-
ers to modify their approaches in response to 
observed changes. A model system in which the 
response of individual glial cells to engrafted 
cell therapies can be assessed in a controlled 
environment would provide useful information 
about how glia respond to cells from different 
sources or at different stages of differentiation. 
This would complement knowledge about effi-
cacy that can be gained from other co-culture 
approaches (e.g., support of neuronal growth), 
and would allow greater refinement of cell thera-
pies in vitro prior to testing in vivo, thus reducing 
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the cost, time and reliance on animal models at 
early stages of therapy development. 
Astrocytes are the principal cells responsible 
for mediating glial scar formation, but it is dif-
ficult to predict the extent of astrocyte response 
to a potential therapy using traditional cell cul-
ture approaches, where astrocytes exhibit a highly 
reactive phenotype. Previously we have developed 
a 3D culture system in which astrocytes can be 
maintained in a less reactive manner than in 
2D culture and, when stimulated, undergo a 
classical reactive response reminiscent of their 
behavior in vivo [11,12]. Here we have adapted this 
approach to provide a co-culture system to assess 
the response of astrocytes to potential stem cell 
therapies. Having established robust protocols for 
generating and monitoring the model, it was vali-
dated using peripheral nervous system glia, which 
are known to elicit a substantial astrocyte response 
[13], then used to assess the response of astrocytes 
to three typical examples of cell therapies that are 
currently under investigation for CNS repair: neu-
ral crest stem cells (NCSCs) from hair follicles [14], 
differentiated Schwann cell-like adipose-derived 
stem cells (dADSCs) [15] and mesenchymal stem 
cells from bone marrow (BM-MSCs) [16].
Materials & methods
n Astrocyte cultures
Experiments were performed according to the 
UK Animals (Scientific Procedures) Act (1986) 
and approved by the Open University animal 
ethics advisory group. Sprague–Dawley rats 
(a b-actin–GFP reporter line or wild-type) 
were used from established in-house breeding 
colonies. Primary astrocyte cultures were pre-
pared from postnatal 2-day-old rat cortices as 
described previously [11]. Cells were maintained 
in DMEM (Gibco, Life Technologies, CA, USA) 
supplemented with penicillin and streptomycin 
(100 U/ml and 100 mg/ml, respectively; Sigma-
Aldrich, MO, USA) and 10% v/v fetal calf serum 
(standard culture medium) in 75 cm2 flasks 
(Greiner Bio-One Ltd, UK) coated with poly-d-
lysine (Sigma-Aldrich). After 8 days, cells reached 
confluence and flasks were shaken at 150 rpm for 
4 h to detach microglia and less adherent cells. 
Resulting cultures were 95% astrocytes and 5% 
microglia (as determined by immunoreactivity for 
GFAP and lectin IB4, respectively). Cells were 
trypsinized, washed and counted prior to seeding 
into collagen gels.
n Stem cell cultures
BM-MSCs from adult female Fisher 344 rats were 
obtained from Merck Millipore (MA, USA) and 
cultured in Mesenchymal Stem Cell Expansion 
Media (Merck Millipore). Nutrient medium was 
replaced every 2–3 days until cells were approxi-
mately 80% confluent, as observed under phase-
contrast microscopy. Cells were removed with 
3 ml Accutase™ (Chemicon, Merck Millipore) 
for 5 min at 37°C and recovered by centrifugation 
at 300 × g for 5 min.
NCSCs were obtained from the whisker 
hair follicles of adult Sprague–Dawley rats 
(250–300 × g). They were cultured as described 
previously [17], except that the culture medium 
was supplemented with 10 ng/ml bFGF.
The dADSCs were prepared as described previ-
ously [18] and were maintained in DMEM supple-
mented with 10 µM forskolin (Sigma-Aldrich), 
10 ng/ml bFGF (Invitrogen, Life Technologies) 
and 100 ng/ml neuregulin-1 (R&D Systems) 
until approximately 80% confluent. Cells were 
harvested for use before passage 8 with 0.25% 
Trypsin–EDTA solution for 7–10 min at 37°C. 
Cells were recovered by centrifugation at 400 × g 
for 5 min and the pellet was resuspended in 
standard culture medium.
n 3D cell cultures
Astrocytes were seeded at 2 × 106 cells/ml within 
type I collagen gels as described previously [11,12]. 
Gels were cast in 24-well plates (1.5 ml/well; 
resulting in gels approximately 4-mm thick) before 
placing at 37°C to set (~5 min). Wells were topped 
up with standard culture medium, after first add-
ing a 100-µl suspension of the control (additional 
astrocytes or Schwann cells) or test stem cells to 
the surface of gels. Either the astrocytes within 
the gels or the cells seeded onto the surface were 
prepared from GFP animals, providing a means to 
distinguish between cell populations during sub-
sequent ana lysis (Supplementary Figure 1; see onlineat 
www.futuremedicine.com/doi/suppl/10.2217/
rme.13.61). Cultures were maintained at 37°C, 
5% CO
2
 for 5 days with media replaced daily. 
Initial experiments assessed the effect of adding 
additional astrocytes (negative control), Schwann 
cells (positive control) or no cells to the surface of 
the gels. Astrocytes were seeded onto the surface 
of gels at 1 × 105 cells in 100 µl. The rat Schwann 
cell line SCL 4.1/F7 (Health Protection Agency, 
UK) was maintained in standard culture medium 
and seeded onto the surface of gels at 2 × 104 cells 
in 100 µl.
n Immunodetection of GFAP
After 5 days in culture, medium was removed and 
gels were fixed in 4% paraformaldehyde following 
a brief rinse in phosphate-buffered saline. A slice 
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was removed from the center of each gel (Figure 1) 
and immunofluorescence staining to detect 
GFAP was conducted as described previously 
[11]. Hoechst 33258 (Sigma-Aldrich) was included 
with the secondary antibody to label cell nuclei.
Confocal microscopy following a predefined 
protocol was performed using a Leica TCS SP5 
confocal microscope (Leica Microsystems, Ger-
many) to sample designated fields within the 
gel slices (Figure 1). Fields for quantification were 
0.77 × 0.77 × 0.04 mm (XYZ) with one image 
per 1 µm in the Z direction. Three fields were 
sampled at the top edge of the gel slice where 
the astrocytes were in contact with the test cells. 
Equivalent fields, 1 mm from the bottom edge of 
the gel, were also sampled for comparison with 
the top fields to assess whether cellular responses 
were contact- and/or distance-dependent. Vol-
ume of GFAP immunoreactivity was measured 
using automated ana lysis protocols (Volocity 6.1, 
Perkin-Elmer, MA, USA) as described previously 
[12]. Cell number was determined by counting 
Hoechst stained nuclei so GFAP volumes could be 
expressed per cell (Supplementary table 1). GFP label-
ing was used to distinguish between astrocytes 
within the gel and test cells applied to the surface, 
to ensure that only astrocytic GFAP and astrocyte 
nuclei were included in the analyses. A minimum 
of five independent gels were analyzed from at 
least two separate cell preparations in each case. 
n Statistical ana lysis
Data were analyzed using GraphPad Prism® 
software (Prism 5, GraphPad Software, Inc., 
CA, USA). Normality and quality of variance 
tests were performed on all data to determine 
which test was appropriate. A paired t-test was 
used with significance level 95% for comparison 
between the top and bottom regions within gels. 
An analysis of variance with Tukey’s multiple 
comparison test was performed with significance 
level 95% to compare the top and bottom regions 
between gels that had received different test cell 
populations (or controls with Schwann cells or 
no added test cells). A Kruskal–Wallis test with 
Dunn’s multiple comparison test was used with 
significance level 95% to compare astrocyte num-
bers between groups. All values are indicated as 
mean ± standard error of the mean. 
Results
Co-cultures with astrocytes in a 3D collagen gel 
and control or test cells seeded on top were set up 
and analyzed as demonstrated in Figure 1. Stem cell 
populations were prepared according to previously 
established protocols and characterized by detec-
tion of immunoreactivity to markers as follows: 
NCSCs (SOX10+), BM-MSCs (CD54+, integrin 
b1+, CD45- and CD14-) and dADSCs (S100+, 
GFAP+, p75+ and SOX10+).
Initial experiments (Figure 2) showed little dif-
ference in the GFAP volume per astrocyte after 
5 days when 1 × 105 astrocytes were added to the 
surface of the gels compared with control gels 
with no additional cells seeded on top. This con-
firmed that any response of astrocytes within the 
gels observed in subsequent experiments was the 
result of the specific cell type under test, rather 
than the presence of a layer of cells per se. The 
number of astrocytes used in this initial test 
was five-times greater than the numbers of test 
cells used in subsequent experiments, providing 
assurance that any localized alterations in oxy-
gen/nutrient levels that might occur owing to 
∼2 mm
∼4 mm
∼4 mm
Layer of stem cells on
top of gel
Top
Bottom
GFP astrocytes within gel
Slice removed
from gel Top sampling
regions
Bottom sampling
regions
Six astrocyte regions
in each gel slice selected
for image capture
(0.77 × 0.77 × 0.04 mm)
Regen. Med. © Future Science Group (2013)
Figure 1. 3D cell culture system. Astrocyte gels were set within 24-well culture plates before 
control or test cells were seeded onto the top surface. Following 5 days in culture, gels were fixed 
and a slice approximately 2-mm thick was removed from the center of each gel for confocal 
microscopy. Images were captured using standardized microscope settings from three positions at 
the top and three positions near the bottom of each gel slice. 
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application of an additional cell layer would not 
affect astrocyte reactivity within the gels. Further-
more, there was no difference in GFAP volume 
per astrocyte between the cells in the top and 
bottom regions of these gels after 5 days, with 
both regions remaining equivalent to controls that 
received no additional cells. 
To investigate whether the parameters used in 
this model system would allow quantification of 
the response of astrocytes to a cell type known to 
trigger reactive gliosis, a Schwann cell line was 
used as a positive control. Five days after 2 × 104 
Schwann cells were seeded onto the astrocyte 
gels, there was an increase in GFAP volume per 
astrocyte compared with control gels, with a 3.5-
fold difference between the GFAP volume per 
astrocyte at the top of the Schwann cell-seeded 
gels compared with the bottom (Figure 2). There 
was a slight increase in GFAP volume per astro-
cyte in the bottom region compared with the 
control condition shown in Figure 2, but this was 
not significant (table 1). Pilot experiments (data 
not shown) also tested 1 × 105 Schwann cells 
in this experiment; a greater increase in GFAP 
volume was observed but due to the adequate 
distinction between Schwann cell and control 
conditions (Figure 2), and in order to minimize 
the numbers of test cells required in subsequent 
experiments, the density of 2 × 104 cells per 
100 µl was used for the experiments described 
hereafter.
The effect of adding NCSCs, dADSCs 
or BM-MSCs (2 × 104 cells in 100 µl) to the 
surface of the astrocyte gels was determined 
(Figure 3) and table 1 summarizes the results of 
comparing both the top and the bottom regions 
between the groups (and controls). BM-MSCs 
caused a significant twofold increase in GFAP 
volume per astrocyte at the top of the gels com-
pared with the bottom of the same gels and 
also a sixfold increase compared with the top 
of the control gels (no added cells). There was 
a significant increase in astrocytic GFAP vol-
ume in fields at the bottom of the BM-MSCs 
compared with the bottom of control gels 
and the relative responses of the top and bot-
tom fields may indicate a gradient of response 
to some secreted factor originating from the 
BM-MSCs or proximal astrocytes responding 
to these cells. The level of GFAP per astrocyte 
in the top fields in co- cultures with BM-MSCs 
was equivalent to that in Schwann cell-positive 
controls (Figure 2 & table 1). Neither the NCSCs 
nor the dADSCs caused a significant increase in 
GFAP per astrocyte at the top of the gels com-
pared with controls (table 1), although there was 
a slight increase in GFAP per astrocyte in the 
dADSC condition (not significant). Interest-
ingly, there was a difference in GFAP per astro-
cyte between the top and bottom regions of the 
gels that received NCSCs, although this appears 
to be due to a slightly reduced GFAP volume 
per astrocyte in the bottom region (which was 
not significant when compared with the bottom 
regions of the other conditions; table 1). 
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Figure 2. Astrocyte reactivity in response to control cells. (A) Astrocytic 
GFAP immunoreactivity (red) was detected after 5 days in the absence of cells 
(control), or in response to astrocytes (negative control) or Schwann cells (positive 
control) seeded onto the top of the gels. Scale bars = 100 µm. (B) Astrocytes 
within the gels were distinguished from cells seeded on the surface using GFP, and 
nuclei were stained using Hoechst (blue). Confocal image series were analyzed to 
quantify the volume of GFAP immunoreactivity per astrocyte within the gel regions. 
Three replicate series were analyzed within each region (top and bottom) of each 
gel and data are means ± standard error of the mean from at least five independent 
gels. Top and bottom regions were compared using a paired t-test. Please see color 
figure at www.futuremedicine.com/doi/pdf/10.2217/rme.13.61. 
*p < 0.05. 
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Discussion
The results show that astrocytes in 3D collagen 
gels respond to cell populations seeded onto their 
surface, providing a useful model for compar-
ing the extent to which different cell types can 
trigger reactive gliosis. Astrocytes in control 
gels showed a relatively unreactive phenotype 
after 5 days, which is consistent with previous 
reports [11], but when stimulated by the pres-
ence of Schwann cells the adjacent astrocytes 
adopted a classical ramified reactive phenotype 
with increased GFAP volume per cell. This is 
similar to the response of astrocytes adjacent to 
a dissociated dorsal root ganglion (DRG) culture 
demonstrated previously in another 3D culture 
system [12], and reminiscent of their behavior 
following CNS damage in vivo [19]. 
When other cell types were tested as exam-
ples of potential cell therapies it was possible to 
identify differences in their ability to modulate 
astrocyte reactivity. Of the cells tested, BM-
MSCs elicited the greatest astrocyte response, 
with dADSCs and NCSCs being equivalent to 
unstimulated controls. In those groups where an 
increase in astrocyte reactivity was observed, the 
response was limited to the astrocytes adjacent to 
the cells under test. This suggests that the effect 
may be mediated by direct physical contact 
between cells rather than through the action of 
diffusible molecules, although the latter cannot 
be ruled out. The model described here could 
be used to investigate the mechanisms under-
pinning the astrocyte response; for example, 
through the application of conditioned media 
from cultures of the cells under test. In a previ-
ous study we showed that conditioned media 
from DRG cultures failed to elicit the astrocyte 
response that was observed when DRG cells and 
astrocytes were co-cultured in direct contact [12].
BM-MSC populations have been associated 
with both increased and reduced glial scarring 
in vivo [20–25] and in vitro [26]. It is possible that 
the observation here that direct contact between 
BM-MSCs and astrocytes in 3D culture for 
5 days increases reactive gliosis may help to 
explain some of the diverse effects observed in 
other models. Schwann cells have been exten-
sively tested for cellular therapy of spinal cord 
injury (reviewed in [27]); they can remyelin-
ate damaged axons and provide a permissive 
environment for axon growth. However, axons 
regenerating into Schwann cell grafts fail to re-
enter the host spinal cord, most likely as a result 
of the Schwann cells potentiating the glial scar 
reaction, consistent with the results shown here. 
Autologous Schwann cell transplants necessitate 
the sacrifice of a peripheral nerve; therefore, 
alternative methods to generate Schwann cells 
have been investigated, such as dADSCs. It is 
interesting that while these resemble Schwann 
cells morphologically and in terms of expression 
of characteristic marker proteins [18], they dif-
fered considerably from the Schwann cells used 
in this study in terms of their ability to elicit 
reactive astrogliosis in 3D culture. A previous 
study, in which similar cells were tested in a rat 
contusion brain injury model, showed a reduc-
tion in reactive gliosis [15]. The model described 
Table 1. Statistical comparison of the astrocyte response using Tukey’s multiple 
comparison test.
Schwann cells NCSCs dADSCs BM-MSCs
Top
Control ** NS NS **
BM-MSC NS ** * –
dADSC ** NS – –
NCSC *** – – –
Bottom
Control NS NS NS *
BM-MSC NS ** NS –
dADSC NS NS – –
NCSC NS – – –
GFAP volume per astrocyte was compared between groups for both the top and the bottom regions of the gels using 
one-way analysis of variance. Tukey’s multiple comparison test was used to compare astrocyte reactivity between all test 
groups as well as the controls with no cells or Schwann cells on top. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
BM-MSC: Mesenchymal stem cell from bone marrow; dADSC: Differentiated Schwann cell-like adipose-derived stem cell; 
NCSC: Neural crest stem cell; NS: Nonsignificant.
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here could potentially be used to explore whether 
dADSCs or other cell types are able to directly 
reduce the response of reactive astrocytes in vitro 
(e.g., following stimulation with TGF-b1) [11]. 
As these cells potentially mimic the neuroregen-
erative properties of Schwann cells without trig-
gering the astrocyte responses associated with 
them, it would be interesting to explore their use 
in treating other CNS injuries. Another study 
showed that Schwann cells differentiated from 
nestin-positive spheroid structures derived from 
adipose stem cells could myelinate spinal cord 
axons [28]. Neurally induced adipose stem cells 
also have some beneficial effects on spinal cord 
repair [29], but how these cells influenced the 
glial scar was not determined. Given the abun-
dance of adipose tissue that can be harvested 
with minimal morbidity and the ease of stem 
cell extraction for differentiation to a Schwann 
cell-like phenotype, we believe that dADSCs are 
a potentially useful cell source for treatment of 
CNS injuries.
NCSCs from skin offer another exciting pos-
sibility for CNS regeneration owing to their 
capacity to give rise to both neurons and glia 
[30], but despite having been used in experimen-
tal models for treating spinal cord trauma [14,31], 
little is known about their interaction with host 
astrocytes. Our findings indicate that they do 
not increase astrocyte reactivity during 5 days of 
contact in vitro. In this context it is interesting to 
note that specialized neural crest cells transiently 
populate the peripheral nervous system–CNS 
interface of the spinal cord, without gliosis, dur-
ing a developmental window when DRG neu-
rites grow into the CNS. It is only once these 
cells have disappeared and Schwann cells abut 
the CNS that neurite regeneration into the CNS 
is prohibited and is associated with gliosis [32]. 
While it is interesting to note the differences 
in astrocyte response elicited by the cell types 
tested here, it is important not to overinterpret 
these observations, since they were based on a 
single time point and a specific protocol for test 
cell preparation, and cells remained in vitro. Fur-
thermore, although it is useful to understand the 
direct effect of a potential cell therapy on astro-
cytes in culture, it is important to consider the 
following: other cell types such as microglia are 
critical mediators of the glial response in vivo; 
the behavior and differentiation of the test cells 
in vivo may differ from in vitro; and the starting 
cell populations used here may be different to 
those used in other studies. Notwithstanding 
these limitations, the culture system developed 
here provides a novel tool for assessing an impor-
tant aspect of CNS cell therapy and could be 
used for understanding fundamental cell biology 
involved in reactive gliosis.
Conclusion
The principal finding is that this 3D culture 
system is suitable for screening potential thera-
peutic cells prior to in vivo testing, allowing 
cell populations likely to trigger a substantial 
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Figure 3. Astrocyte reactivity in response to test cell populations. 
(A) Astrocytic GFAP immunoreactivity (red) was detected in defined locations 
within gels after 5 days in response to NCSCs, dADSCs or BM-MSCs seeded onto 
the top of gels. Astrocytes within the gels were distinguished from cells seeded on 
the surface using GFP, and nuclei were stained using Hoechst (blue). Scale 
bars = 100 µm. (B) Confocal image series were analyzed to quantify the volume of 
GFAP immunoreactivity per astrocyte within the gel regions. Three replicate series 
were analyzed within each region (top and bottom) of each gel and data are 
means ± standard error of the mean from at least six independent gels. Top and 
bottom regions were compared using a paired t-test. Please see color figure at 
www.futuremedicine.com/doi/pdf/10.2217/rme.13.61. 
**p < 0.01; ***p < 0.001.  
BM-MSC: Mesenchymal stem cell from bone marrow; dADSC: Differentiated 
Schwann cell-like adipose-derived stem cell; NCSC: Neural crest stem cell.
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astrocyte response to be identified at an early 
stage. The model system presented here is 
simple enough to encourage widespread adop-
tion, requiring standard cell culture equipment 
and simple protocols for analyzing astrocyte 
responses. It should be of interest to research-
ers wishing to develop cell therapies for CNS 
damage and disease, or those involved in 
understanding astrocyte biology.
Future perspective
Given the growing interest in the use of ther-
apeutic cells to treat chronic neurological 
injuries/diseases, there is increasing demand for 
experimental models that can be used to screen 
for the most promising candidates. It is likely 
that researchers will continue to seek to reduce 
reliance on animal models for ethical and practi-
cal reasons, so it is predicted that noninvasive 
in vitro models will form the initial test system 
of choice. 3D culture models permit continu-
ous monitoring of specific cellular responses and 
interactions in a more physiologically relevant 
spatial arrangement than simpler cultures. In 
the future, the 3D model described here will 
lend itself to the inclusion of other CNS cell 
types, and to building up levels of complexity by 
investigating how co-cultures of CNS cells can 
respond to different therapeutic cell types. New 
technologies that yield cultures of human neural 
cells for research into CNS disorders will pro-
vide an opportunity to avoid limitations associ-
ated with using animal cells to model human 
conditions. Scaling, automation and commer-
cial supply of 3D culture systems will facilitate 
their widespread adoption for routine use. We 
expect that increased utilization of these types 
of models will help to ensure that only suitable 
candidate therapeutic cells will be taken forward 
into preclinical in vivo testing.
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Executive summary
Background
  Astrocytes in 3D collagen gels can respond to cell therapy populations seeded onto their surface.
Methods
  Changes in astrocyte reactivity were monitored 5 days after addition of neural crest stem cells, differentiated Schwann cell-like 
adipose-derived stem cells, bone marrow stem cells or control Schwann cells.
Results
  Neural crest stem cells did not cause any increase in the levels of the astrocyte activation marker. 
  Differentiated Schwann cell-like adipose-derived stem cells did not increase astrogliosis.
  Bone marrow stem cells elicited substantial reactive gliosis, with a twofold increase in levels of the astrocyte activation marker.
  Schwann cells triggered a 3.5-fold increase in reactive gliosis as a positive control for system validation.
Discussion
  Neural crest stem cells and differentiated Schwann cell-like adipose-derived stem cells may be useful therapeutic cells for treating CNS 
injuries without exacerbation of reactive astrogliosis. 
  This system provides a useful model for comparing the extent to which different cell types can elicit reactive astrogliosis.
  This model is suitable for screening potential therapeutic cells prior to in vivo testing, allowing cell populations likely to trigger a 
substantial astrocyte response to be identified at an early stage.
  The results presented should encourage widespread adoption of such models.
www.futuremedicine.com 745future science group
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